Brand Name | Status | Last Update |
---|---|---|
2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w... | Biologic Licensing Application | 2011-03-11 |
ad incontinence support | C200263 | 2025-03-07 |
avance incontinence care | C200263 | 2024-05-11 |
bioelements, inc. | OTC monograph not final | 2012-01-17 |
ca-rezz - long term care - incontinent cleanser | C200263 | 2024-12-26 |
ca-rezz - norisc - incontinent wash | C200263 | 2024-12-27 |
center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al... | Biologic Licensing Application | 2009-06-12 |
chain drug marketing association, inc. | C200263 | 2025-08-22 |
crooked creek distillery inc hand sanitizer | OTC monograph not final | 2020-03-25 |
cvs pharmacy,inc. | C200263 | 2024-08-16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 17 | — | — | 1 | — | 18 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | — | 1 | — | 1 |
Urinary incontinence | D014549 | — | R32 | — | — | — | 1 | — | 1 |
Enuresis | D004775 | — | R32 | — | — | — | 1 | — | 1 |
Macular edema | D008269 | — | — | — | — | — | 1 | — | 1 |
Dry eye syndromes | D015352 | — | H04.12 | — | — | — | 1 | — | 1 |
Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rosacea | D012393 | — | L71 | — | — | 3 | — | — | 3 |
Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 2 | — | — | 2 |
Actinic keratosis | D055623 | — | L57.0 | — | — | 2 | — | — | 2 |
Keratosis | D007642 | — | — | — | — | 2 | — | — | 2 |
Erythema | D004890 | — | L53.9 | — | — | 1 | — | — | 1 |
Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
Allergic rhinitis | D065631 | — | J30.9 | — | — | 1 | — | — | 1 |
Rhinitis | D012220 | EFO_0008521 | J31 | — | — | 1 | — | — | 1 |
Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | — | 1 | — | — | 1 |
Ankle injuries | D016512 | — | S93.4 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
Drug common name | Enoblituzumab |
INN | enoblituzumab |
Description | Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3545373 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | M6030H73N9 (ChemIDplus, GSRS) |